Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma

Tolinapant (ASTX660) is a potent, nonpeptidomimetic antagonist of cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) and X-linked IAP, which is currently being evaluated in a phase 2 study in T-cell lymphoma (TCL) patients. Tolinapant has demonstrated evidence of single-agent clinical activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Nicola, Ward, George, Gewinner, Christina, Davis, Matthew P., Jueliger, Simone, Saini, Harpreet, Munck, Joanne, Smyth, Tomoko, Ferraldeschi, Roberta, Keer, Harold, Lyons, John, Sims, Martin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945623/
https://www.ncbi.nlm.nih.gov/pubmed/34474469
http://dx.doi.org/10.1182/bloodadvances.2020003955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945623/
https://www.ncbi.nlm.nih.gov/pubmed/34474469
http://dx.doi.org/10.1182/bloodadvances.2020003955

Ejemplares similares